Comparative analysis of genes frequently regulated by drugs based on connectivity map transcriptome data

Gene expression is perturbated by drugs to different extent. Analyzing genes whose expression is frequently regulated by drugs would be useful for the screening of candidate therapeutic targets and genes implicated in side effect. Here, we obtained the differential expression number (DEN) for genes profiled in Affymetrix microarrays from the Connectivity Map project, and conducted systemic comparative computational analysis between high DEN genes and other genes. Results indicated that genes with higher down-/up-regulation number (down_h/up_h) tended to be clustered in genome, and have lower homologous gene number, higher SNP density and more disease-related SNP. Down_h and up_h were significantly enriched in cancer related pathways, while genes with lower down-/up-regulation number (down_l/up_l) were mainly involved in the development of nervous system diseases. Besides, up_h had lower interaction network degree, later developmental stage to express, higher tissue expression specificity than up_l, while down_h showed reversed tendency in comparison with down_l. Together, our analysis suggests that genes frequently regulated by drugs are more likely to be associated with disease-related functions, but the extensive activation of conserved and widely expressed genes by drugs is disfavored.

[1]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..

[2]  Sven Bergmann,et al.  A modular approach for integrative analysis of large-scale gene-expression and drug-response data , 2008, Nature Biotechnology.

[3]  Johan Staaf,et al.  GOBO: Gene Expression-Based Outcome for Breast Cancer Online , 2011, PloS one.

[4]  W. El-Deiry,et al.  In vitro evaluation of a p53‐expressing adenovirus as an anti‐cancer drug , 1996, International journal of cancer.

[5]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[6]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[7]  A. Hannan,et al.  Nature, nurture and neurology: gene–environment interactions in neurodegenerative disease , 2005, The FEBS journal.

[8]  Yang Li,et al.  HMDD v2.0: a database for experimentally supported human microRNA and disease associations , 2013, Nucleic Acids Res..

[9]  Quan Zou,et al.  Which statistical significance test best detects oncomiRNAs in cancer tissues? An exploratory analysis , 2016, Oncotarget.

[10]  Zhiyong Lu,et al.  Database resources of the National Center for Biotechnology Information , 2010, Nucleic Acids Res..

[11]  Ying Ju,et al.  Accurate Identification of Cancerlectins through Hybrid Machine Learning Technology , 2016, International journal of genomics.

[12]  Joshua F. McMichael,et al.  DGIdb - Mining the druggable genome , 2013, Nature Methods.

[13]  D. Givol,et al.  The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[14]  I. Jurisica,et al.  Network-based characterization of drug-regulated genes, drug targets, and toxicity. , 2012, Methods.

[15]  Xing Chen,et al.  NLLSS: Predicting Synergistic Drug Combinations Based on Semi-supervised Learning , 2016, PLoS Comput. Biol..

[16]  Jihye Kim,et al.  DSigDB: drug signatures database for gene set analysis , 2015, Bioinform..

[17]  Xiangxiang Zeng,et al.  Integrative approaches for predicting microRNA function and prioritizing disease-related microRNA using biological interaction networks , 2016, Briefings Bioinform..

[18]  D. Pim,et al.  Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. , 1984, The EMBO journal.

[19]  R. Beroukhim,et al.  Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins , 2014, Nature Genetics.

[20]  Tae-Wook Kang,et al.  GENT: Gene Expression Database of Normal and Tumor Tissues , 2011, Cancer informatics.

[21]  Peer Bork,et al.  OGEE: an online gene essentiality database , 2011, Nucleic Acids Res..

[22]  Xing Chen,et al.  Drug-target interaction prediction by random walk on the heterogeneous network. , 2012, Molecular bioSystems.

[23]  F. Speleman,et al.  A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma , 2013, PloS one.

[24]  Sudha Seshadri,et al.  Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study , 2012, BMJ : British Medical Journal.

[25]  Yuan Zhou,et al.  Identification and analysis of the human sex-biased genes , 2016, Briefings Bioinform..

[26]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[27]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[28]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[29]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[30]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[31]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Syed Haider,et al.  Ensembl BioMarts: a hub for data retrieval across taxonomic space , 2011, Database J. Biol. Databases Curation.

[33]  Yongdong Zhang,et al.  Drug-target interaction prediction: databases, web servers and computational models , 2016, Briefings Bioinform..

[34]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[35]  Kara Dolinski,et al.  The BioGRID interaction database: 2017 update , 2016, Nucleic Acids Res..

[36]  T. Owa.  [Drug target validation and identification of secondary drug target effects using DNA microarrays]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[37]  M. Isobe,et al.  Localization of gene for human p53 tumour antigen to band 17p13 , 1986, Nature.

[38]  P. Stenson,et al.  Human Gene Mutation Database (HGMD®): 2003 update , 2003, Human mutation.

[39]  Carlo Caltagirone,et al.  Inverse occurrence of cancer and Alzheimer disease , 2013, Neurology.